Targeting NUPR1 for Cancer Treatment: A Risky Endeavor.
Abstract NUPR1 is a transcription factor that has attracted great attention because its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 regulates a complex network of pathways that may be affected by its silencing, which can cause varying effects. Its role in some types of cancer has been reported but remains incompletely understood whereas its roles in other types of cancers have not been reported yet. Therefore, targeting NUPR...
Source: Current Cancer Drug Targets - July 3, 2020 Category: Cancer & Oncology Authors: Mansour SMA, Ali SA, Nofal S, Soror SH Tags: Curr Cancer Drug Targets Source Type: research

Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
CONCLUSION: In patients with metastatic colorectal cancer, selinexor on this dose schedule plus mFOLFOX6 was not tolerable. Other dosing schedules or combinations may be evaluated. Clinical trial identifier NCT02384850. PMID: 32598257 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - June 27, 2020 Category: Cancer & Oncology Authors: Nilsson S, Stein A, Rolfo C, Kranich A, Mann J, Papadimitriou K, Theile S, Amberg S, Bokemeyer C Tags: Curr Cancer Drug Targets Source Type: research

Emerging Multi-Cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
Abstract RNA binding proteins (RBPs) associate with nascent and mature RNAs to perform biological functions such as alternative splicing and RNA stability. Having unique RNA recognition binding motifs, RBPs form complexes with RNA in a sequence- and structure-based manner. Aberrant expressions of several RBPs have been identified in tumorigenesis and cancer progression. These uncontrolled RBPs affect several mechanisms, including cell proliferation, tumor growth, invasion, metastasis and chemoresistance. Epithelial splicing regulatory protein 1 (ESRP1) is a member of the hnRNP family of proteins that play a crucia...
Source: Current Cancer Drug Targets - June 21, 2020 Category: Cancer & Oncology Authors: Vadlamudi Y, Dey DK, Kang SC Tags: Curr Cancer Drug Targets Source Type: research

The Roles of Alternative Splicing in Tumor-immune Cell Interactions.
Abstract Alternative splicing (AS) plays a significant role in the hallmarks of cancer and can provide neoantigens for immunotherapy. Here, we summarize recent advances in immune system associated tumor specific-antigens (TSAs) produced by AS. We further discuss the regulating mechanisms involved in AS-mediated innate and adaptive immune responses and the anti-tumoral and pro-tumoral roles in different types of cancer. For example, ULBP1_RI, MLL5△21spe, NKp44-1△5, MHC-I△7, CD200S△1, 2, PVR α/β/γ/δ and IL-33 variants 1/2/3 act as regulators in solid tumors and IPAK4-L and, FOXP1&Delta...
Source: Current Cancer Drug Targets - June 19, 2020 Category: Cancer & Oncology Authors: Wang Y, Zhang H, Jiao B, Nie J, Li X, Wang W, Wang H Tags: Curr Cancer Drug Targets Source Type: research

Targeting MUC15 Protein in Cancer: Molecular Mechanisms and Therapeutic Perspectives.
Abstract MUC15, a member of the mucin family, is a heavily glycosylated transmembrane protein with the primary functions of lubricating surfaces, establishing a selective molecular barrier at the epithelium and mediating signal transduction. Aberrant expression of MUC15 plays a crucial role in the progression of multiple diseases including malignant tumors. MUC15 has been identified as a tumor suppressor, but current evidences indicate that its function as an oncogene in different types of cancers. MUC15 has been shown to be involved in the development of cancer and influence cellular growth, adhesion, invasion, m...
Source: Current Cancer Drug Targets - June 1, 2020 Category: Cancer & Oncology Authors: Zhang S, Zhang W, Xiao Y, Qin T, Yue Y, Qian W, Shen X, Ma Q, Wang Z Tags: Curr Cancer Drug Targets Source Type: research

Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: one case report and literature review.
CONCLUSIONS: This novel drug might be a useful method to allow doctors to guarantee a better chance for long-term survival in recurrent, metastatic HCC patients with previous LT. However, it should be used with caution in allograft recipients due to the risk of acute graft rejection, further larger, prospective studies are needed to determine optimal immunomodulatory therapy to achieve optimal anti-tumor efficacy with transplant liver preservation. PMID: 32433005 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 19, 2020 Category: Cancer & Oncology Authors: Qiu J, Tang W, Du C Tags: Curr Cancer Drug Targets Source Type: research

FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Abstract Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in 30% of acute myeloid leukaemia (AML) patients at diagnosis and confer an adverse clinical prognosis. Mutated FLT3 has emerged as a viable therapeutic target and a number of FLT3-directed tyrosine kinase inhibitors have progressed through clinical development over the last 10-15 years. The last two years have seen United States Food and Drug Administration (US FDA) approvals of the multi-kinase inhibitor midostaurin for newly-diagnosed FLT3-mutated patients when used in combination with intensive chemotherapy, and of the more FLT3-sel...
Source: Current Cancer Drug Targets - May 17, 2020 Category: Cancer & Oncology Authors: Hogan FL, Williams V, Knapper S Tags: Curr Cancer Drug Targets Source Type: research

CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia.
CONCLUSION: These findings indicate that polymorphic CYP1A1 and CYP2D6 genes affect the susceptibility to CML. PMID: 32418524 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 17, 2020 Category: Cancer & Oncology Authors: Idris HM, Khalil HB, Mills J, Elderdery AY Tags: Curr Cancer Drug Targets Source Type: research

Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Abstract Triple negative breast cancer (TNBC) is one of the most aggressive subtype of breast cancer accounting for 15-20% of cases and is defined by the lack of hormonal receptors viz., estrogen receptor (ER), progesterone receptor (PR) and expression of human epidermal growth receptor 2 (HER2). Treatment of TNBC is more challenging than other subtypes of breast cancer due to the lack of markers for the molecularly targeted therapies (ER, PR, and HER-2/ Neu), the conventional chemotherapeutic agents are still the mainstay of the therapeutic protocols of its patients. Despite, TNBC being more chemo-responsive than...
Source: Current Cancer Drug Targets - May 17, 2020 Category: Cancer & Oncology Authors: Mir M, Khan H, Mehraj U, Nisar S, Bhat B, Wani N Tags: Curr Cancer Drug Targets Source Type: research

Strategic combination therapies for ovarian cancer.
Abstract Ovarian cancer remains the leading cause of gynecologic cancer-related death among women worldwide. The dismal survival rate is partially due to recurrence after standardized debulking surgery and first-line chemotherapy. In recent years, targeted therapies including antiangiogenic agents or poly (ADP-ribose) polymerase inhibitors represent breakthroughs in the treatment for ovarian cancer. As more therapeutic agents become available supplemented by deeper understanding of ovarian cancer biology, a range of combination treatment approaches are being actively investigated to further improve the clinical ou...
Source: Current Cancer Drug Targets - May 10, 2020 Category: Cancer & Oncology Authors: Li X, Angel Sn Ng, Mak VC, Chan KK, Cheung AN, Cheung LW Tags: Curr Cancer Drug Targets Source Type: research

Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
CONCLUSION: Hepatitis C virus infection is an independent prognostic factor for EFS and OS in diffuse large B-cell lymphoma. HCV treatment is associated with higher EFS and OS but can't be consider as an independent prognostic factor. PMID: 32392114 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 10, 2020 Category: Cancer & Oncology Authors: Elbedewy TA, A Elashtokhy HE, Abd-Elsalam S, Suliman MA Tags: Curr Cancer Drug Targets Source Type: research

Targeted drug therapy to overcome chemoresistance in Triple Negative Breast Cancer.
Abstract Triple Negative Breast Cancer (TNBC) is the most aggressive and prevailing breast cancer subtype. The chemotherapeutics used in the treatment of TNBC suffer with chemoresistance, dose limiting toxicities and off-target side effects. As a result, conventional chemotherapeutics are unable to prevent tumor growth, metastasis and result in failure of therapy. Various new targets such as BCSCs surface markers (CD44, CD133, ALDH1), signaling pathways (IL-6/JAK/STAT3, notch), pro and anti-apoptotic proteins (Bcl-2, Bcl-xL, DR4, DR5), hypoxic factors (HIF-1α, HIF2α) and drug efflux transporters (ABCC1...
Source: Current Cancer Drug Targets - May 6, 2020 Category: Cancer & Oncology Authors: Kumari M, Krishnamurthy PT, Sola P Tags: Curr Cancer Drug Targets Source Type: research

Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.
Abstract Tumor recurrence and drug resistance are two of the key factors affecting the prognosis of cancer patients. Cancer stem cells (CSCs) are a group of cells with infinite proliferation potential which are not sensitive to traditional therapies including radio- and chemotherapy. These CSCs are considered to be central to tumor recurrence and the development of drug resistance. In addition, CSCs are important targets in cancer immunotherapy because of their expression of novel tumor-associated antigens, which result from mutations in cancer cells over the course of treatment. Emerging immunotherapies, includin...
Source: Current Cancer Drug Targets - May 4, 2020 Category: Cancer & Oncology Authors: Wang W, Bai L, Xu D, Li W, Cui J Tags: Curr Cancer Drug Targets Source Type: research

Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma.
CONCLUSION: We have demonstrated neural stem cell/CSC markers that facilitate the maintenance of cancer stem cells. Developing therapies targeting these factors will help in overcoming resistance and improving retinoblastoma treatment. PMID: 32364077 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 4, 2020 Category: Cancer & Oncology Authors: Balaji S, Santhi R, Kim U, Muthukkaruppan V, Priya CG, Vanniarajan A Tags: Curr Cancer Drug Targets Source Type: research

HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab.
CONCLUSION: HOTAIR can not only promote tumor proliferation, but also enhances the resistance of tumor cells to drugs. Our experimental data not only showed strong expression of HOTAIR in gastric cancer, but also that strong expression of HOTAIR caused the sensitivity of gastric cancer cells to trastuzumab, which is a useful reference for postoperative medication. PMID: 32364078 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 4, 2020 Category: Cancer & Oncology Authors: Bie L, Luo S, Li D, Wei Y, Mu Y, Chen X, Wang S, Guo P, Lu X Tags: Curr Cancer Drug Targets Source Type: research

USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer.
Abstract Ubiquitin specific protease 48 (USP48) is a member of the deubiquitinating enzymes (DUBs) family. However, the function of USP48 in ovarian cancer remains unclear. The present study reveals that USP48 knockdown could significantly inhibit cell migration and invasion in ES2, 3AO and A2780 cells, without affecting cell proliferation. After carboplatin (CBP) treatment, the USP48 ablation increases the apoptosis rate, and the cleaved PARP and cleaved caspase 3 expression levels in ES2, 3AO and A2780 cells. The subcutaneous tumor and intraperitoneally injected experiments demonstrated that the USP48 knockdown ...
Source: Current Cancer Drug Targets - May 2, 2020 Category: Cancer & Oncology Authors: Lei X, Li X, Chen H, Liu Z Tags: Curr Cancer Drug Targets Source Type: research

Vaccine and Cell Based Therapeutic Approaches in Acute Myeloid Leukemia.
Abstract Over the past decade, our increased understanding of the interactions between the immune system and cancer cells has led to paradigm shifts in the clinical management of solid and hematologic malignancies. The incorporation of immune-targeted strategies into the treatment landscape of acute myeloid leukemia (AML), however, has been challenging. While this is in part due to the inability of the immune system to mount an effective tumor-specific immunogenic response against the heterogeneous nature of AML, the decreased immunogenicity of AML cells also represents a major obstacle in the effort to design eff...
Source: Current Cancer Drug Targets - May 1, 2020 Category: Cancer & Oncology Authors: Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H Tags: Curr Cancer Drug Targets Source Type: research

Effect of Nectaroscordum koelzi Methanolic Extract on Acute and Chronic Inflammation in Male Mice.
CONCLUSION: In general, the data from the experiments indicated that the methanol extract of N. koelzi has an anti-inflammatory effect on acute and chronic inflammation. However, the exact contributing mechanisms have not been investigated for the pharmacological effects. PMID: 32357814 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 1, 2020 Category: Cancer & Oncology Authors: Hasanvand KH, Khaksarian M, Alipour M, Mahmoudvand H, Naizi M, Nadri S Tags: Curr Cancer Drug Targets Source Type: research

A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
CONCLUSION: This study identified 13 drugable guava-derived compounds that can be enlisted for further studies as potential HDAC6 and HDAC10 inhibitors. PMID: 32357815 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - May 1, 2020 Category: Cancer & Oncology Authors: Adewole KE, Ishola AA Tags: Curr Cancer Drug Targets Source Type: research

Autophagy driven extracellular vesicles in the leukaemic microenvironment.
Abstract The leukaemias are a heterogenous group of blood cancers which, together, caused 310,000 deaths in 2016. Despite significant research into their biology and therapeutics leukaemia is predicted to account for an increased 470,000 deaths in 2040. Many subtypes remain without targeted therapy, and therefore the mainstay of treatment remains generic cytotoxic drugs with bone marrow transplant the sole definitive option. In this review, we will focus on cellular mechanisms which have the potential for therapeutic exploitation to specifically target and treat this devastating disease. We will bring together the...
Source: Current Cancer Drug Targets - April 28, 2020 Category: Cancer & Oncology Authors: Horton R, Wileman T, Rushworth SA Tags: Curr Cancer Drug Targets Source Type: research

The Therapeutic Potential of MEK1/2 inhibitors in the treatment of gynecological cancers: Rational Strategies and Recent Progress.
Abstract The mitogen-activated protein kinase (MAPK) pathwayis among the key factors in numerous cellular processes involved in tumorigenesis, suggesting it as a potential therapeutic target in gynecological cancer. MAPKs connect gene expression pathways and external stimulations. They include a network consist of Ras, Raf or MAP3K, MEK or MAP2K, ERK or MAPK. Among these,MEK is an attractive molecular target of novel cancer therapeutics as it joints upstream activators and their corresponding downstream targets.MEK inhibitors were among thefirst inhibitors of the MAPK pathway enteringinto clinical trials. Several ...
Source: Current Cancer Drug Targets - April 24, 2020 Category: Cancer & Oncology Authors: Ghanaatgar-Kasbi S, Khazaei M, Rastgar-Moghadam A, Ferns GA, Hassanian SM, Avan A Tags: Curr Cancer Drug Targets Source Type: research

Overexpression of p62 Induces Autophagy and Promotes Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells through Promoting ERK Signaling Pathway.
Abstract BACKGROUND: Increasing evidence has shown that p62 plays an important role in tumorigenesis. However, relatively little is known about the association between p62 and tumor invasion and metastasis; in addition, its role in NPC (nasopharyngeal carcinoma, NPC) has been rarely investigated. OBJECTIVE: To investigate the effect of p62 on tumorigenesis and metastasis in nasopharyngeal carcinoma. METHODS: Western blotting, immunofluorescent staining and immunohistochemistry were used to evaluate p62 protein expression. Subsequently, cell viability, colony formation, migration, invasion and autophagy a...
Source: Current Cancer Drug Targets - April 24, 2020 Category: Cancer & Oncology Authors: Wu Q, Xiang M, Wang K, Chen Z, Long L, Tao Y, Liang Y, Yan Y, Xiao Z, Qiu S, Yi B Tags: Curr Cancer Drug Targets Source Type: research

Targeting isocitrate dehydrogenase mutations (IDH) in AML: wielding the double-edged sword of differentiation.
Abstract The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2). These enzymes are constitutive mediators of basic cellular metabolism, but their mutated forms in cancer synthesize an abnormal metabolite, 2-hydroxyglutarate, that in turn acts as a competitive inhibitor of multiple gene regulatory enzymes. As a result, leukemic IDH mutations cause change...
Source: Current Cancer Drug Targets - April 24, 2020 Category: Cancer & Oncology Authors: Becker JS, Fathi AT Tags: Curr Cancer Drug Targets Source Type: research

The Evolving AML Genomic Landscape: Therapeutic Implications.
Abstract Improved understanding of the genomic and molecular landscape of acute myeloid leukemia (AML) has resulted in significant evolution of our understanding of AML biology and allows refined prognostication for those receiving standard combination chemotherapy induction. This dramatic increase in knowledge preceded, and was somewhat responsible for, at least some of eight new FDA drug approvals for AML. This review discusses the impact of genomics on clinical care of AML patients and highlights newly approved FDA drugs. Despite these recent clinical advances, however, the outcome for most patients diagnosed w...
Source: Current Cancer Drug Targets - April 24, 2020 Category: Cancer & Oncology Authors: Horibata S, Alyateem G, DeStefano CB, Gottesman MM Tags: Curr Cancer Drug Targets Source Type: research

Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy.
Abstract During the last century, our battle against cancer has been inaugurated upon three main approaches; surgery, radiation and chemotherapy. The latest findings on the effectiveness of immunotherapy in cancer management offer a ray of hope after decades of research and studies on the best treatment methods. Immunotherapy has proven effective in the surveillance and destruction of cancer-causing cells, demonstrating its ability to suppress cancer through controlling the well-established immune-editing process. Immuno-editing is a process that comprises three principal elements; namely elimination, equilibrium,...
Source: Current Cancer Drug Targets - April 21, 2020 Category: Cancer & Oncology Authors: Shaaban M, Othman H, Ibrahim T, Ali M, Abdelmoaty M, Abdel-Kawi AR, Mostafa A, El Nakeeb A, Emam H, Refaat A Tags: Curr Cancer Drug Targets Source Type: research

Synthesis and Cytotoxic Activity of Azine Derivatives of 6-Hydroxyxanthanodiene.
CONCLUSION: The conjugates of sesquiterpene lactone 6-hydroxyxanthanodiene III and hydrogenated azines may help to design potential promising anticancer drugs. PMID: 32316892 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 21, 2020 Category: Cancer & Oncology Authors: E Neganova M, Klochkov SG, Pukhov SA, Afanasieva SV, Aleksandrova YR, Yandulova EY, Avila-Rodriguez M, Mikhaleva LM, Nikolenko VN, Somasundaram SG, Kirkland CE, Aliev G Tags: Curr Cancer Drug Targets Source Type: research

Immune Checkpoint Inhibitors in AML-A New Frontier.
Abstract Despite recent therapeutic advancements, acute myeloid leukemia (AML) remains a challenging clinical entity with overall poor outcomes. Given the demonstrable role of T cellmediated immunity in response to allogeneic stem cell transplantation and donor lymphocyte infusions, strategies that enhance immune activation and mitigate immune dysfunction represent attractive therapeutic platforms to improve clinical outcomes in AML. Pre-clinical data suggest that immune dysfunction is a major contributor to AML progression and relapse. Increased expression of immune checkpoints such as programmed death 1 (PD-1) c...
Source: Current Cancer Drug Targets - April 20, 2020 Category: Cancer & Oncology Authors: Thummalapalli R, Knaus H, Gojo I, Zeidner JF Tags: Curr Cancer Drug Targets Source Type: research

VS-5584 Inhibits Human Osteosarcoma Cells Growth by Induction of G1-phase Arrest through Regulating PI3K/mTOR and MAPK Pathways.
CONCLUSIONS: Our findings validated that VS-5584 may be a promising anticancer agent with potential application in the chemotherapy and chemoprevention of human osteosarcoma. PMID: 32286946 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 14, 2020 Category: Cancer & Oncology Authors: Sun JY, Hou YJ, Cui HJ, Zhang C, Yang MF, Wang FZ, Sun Z, Fan CD, Sun BL, Oh JR Tags: Curr Cancer Drug Targets Source Type: research

COVID-19 Pandemic: Experiences in China and implications for its prevention and treatment worldwide.
Abstract The outbreak of COVID-19 due to SARS-CoV-2 originally emerged in Wuhan in December, 2019. As of March 22, 2020, the disease had spread to 186 countries, with at least 305,275 confirmed cases. Although there has been a decline in the spread of the disease in China, the prevalence of COVID-19 around the world remains serious despite containment efforts undertaken by national authorities and the international community. In this article, we systematically review the brief history of COVID-19 and its epidemic and clinical characteristics, highlighting the strategies used to control and prevent the disease in C...
Source: Current Cancer Drug Targets - April 14, 2020 Category: Cancer & Oncology Authors: Liu NN, Tan JC, Li J, Li S, Cai Y, Wang H Tags: Curr Cancer Drug Targets Source Type: research

CircRNA SCARB1 promotes renal cell carcinoma progression via miR-510-5p/SDC3 axis.
CONCLUSION: Circ-SCARB1 promotes RCC progression via sequestering miR-510-5p and indirectly up-regulating SDC3 expression. This provides a novel perspective for the pathogenesis of RCC and potential therapeutic targets for the treatment of RCC. PMID: 32271695 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 9, 2020 Category: Cancer & Oncology Authors: Sun J, Pan S, Cui H, Li H Tags: Curr Cancer Drug Targets Source Type: research

Nanomedicine: a promising avenue for the development of effective therapy for breast cancer.
CONCLUSION: The nanomedicinal approaches are useful over the conventional treatment of breast cancer and deliver a target-specific drug-using different novel drug delivery approach of nanoformulation. PMID: 32228423 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 31, 2020 Category: Cancer & Oncology Authors: Sartaj A, Baboota S, Ali J Tags: Curr Cancer Drug Targets Source Type: research

Study of Toll-like receptor 3 gene polymorphism as a novel risk factor for HCV-related Hepatocellular Carcinoma in Egypt.
CONCLUSION: TLR3 gene SN P +1234C/T could be a novel risk factor for the HCV-related HCC among the Egyptian population. PMID: 32189594 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 18, 2020 Category: Cancer & Oncology Authors: El-Sharawy S, Negm OE, Abd-Elsalam S, El-Sorogy HA, Shehata MAH Tags: Curr Cancer Drug Targets Source Type: research

A review of IGF1 signaling and IGF1-related long noncoding RNAs in chemoresistance of cancer.
Abstract Cancer is still a serious public issue that humans face. Chemoresistance is one of the most important reasons for relapse and poor prognosis. The accumulated data support that the polymorphisms in IGF1 are correlated with both circulating IGF1 levels and cancer risk,and activation of IGF1signaling enhances the progression of cancer. Here, we emphasize the role of IGF1 in resistance to diverse chemotherapies. Dysregulation of IGF1 related lncRNAs may also play an important role in the regulation of chemoresistance by IGF1. Finally, targeting the IGF1 pathway and lncRNAs is effective for increasing the se...
Source: Current Cancer Drug Targets - February 28, 2020 Category: Cancer & Oncology Authors: Liu L, Li X Tags: Curr Cancer Drug Targets Source Type: research

Updated review and perspective on 20S proteasome inhibitors in the treatment of Lung Cancer.
Abstract Lung cancer is the leading cause of cancer-related deaths worldwide. Most lung cancer patients are diagnosed at advanced stages and may benefit from pembrolizumab (anti-PD-1 antibody), cytotoxic chemotherapy and other adjuvant therapies. Despite the availability of various therapies, the response and survival rates have been low. Therefore, study of different targets for the treatment of lung cancer has been one of the major focuses of cancer research. The ubiquitin proteasome system (UPS) is a crucial regulator of cell homeostasis and plays an essential role in growth and development of all cells. The UP...
Source: Current Cancer Drug Targets - February 25, 2020 Category: Cancer & Oncology Authors: Rohondia SO, Ahmed ZSO, Dou QP Tags: Curr Cancer Drug Targets Source Type: research

Uptake of [ ¹⁸F]tetrafluoroborate in MCF-7 Breast Cancer Cells is Induced after Stimulation of the Sodium Iodide Symporter.
CONCLUSION: [18F]TFB was shown to be a promising hNIS-substrate in our model using the human MCF-7 breast cancer cell line mandating in vivo evaluations in xenografted studies and in patients. PMID: 32056515 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 16, 2020 Category: Cancer & Oncology Authors: Lehmacher M, Stolzenburg A, Samnick S Tags: Curr Cancer Drug Targets Source Type: research

CDK9: Therapeutic perspective in HCC therapy.
Abstract CDK9 is an important cell-cycle control enzyme essential in transcription, elongation, and mRNA maturation. Overexpression of CDK9 has been reported in several diseases, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and malignant melanoma. Recent research revealed that CDK9-inhibitors have a major impact on the induction of apoptosis in hepatocellular carcinoma (HCC) cell lines. Despite surprisingly promising results in in vitro and in vivo research, no CDK9 related therapy is currently allowed in cases of HCC. Furthermore, due to their high specificity, the inhibitors had no effec...
Source: Current Cancer Drug Targets - February 12, 2020 Category: Cancer & Oncology Authors: Borowczak J, Szczerbowski K, Stec E, Grzanka D, Szylberg Ł Tags: Curr Cancer Drug Targets Source Type: research

Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications.
Abstract Though modern available cancer therapies are effective, they are connected with major, disagreeable adverse effects, causing non-compliance to patients. Furthermore, the majority of the polymeric-based medication platforms are certainly not universally acceptable, due to their several restrictions. With this juxtaposition, lipid-based medication delivery systems have appeared as promising drug nanocarriers to replace the majority of the polymer-based products because they are in a position to reverse polymer- as well as, drug-associated restrictions. Further, the amalgamation of the basic principle of nan...
Source: Current Cancer Drug Targets - January 15, 2020 Category: Cancer & Oncology Authors: Rajpoot K Tags: Curr Cancer Drug Targets Source Type: research

Fas Ligand Enhances Apoptosis of Human Lung Cancer Cells Cotreated with RIG-I-Like Receptor Agonist and Radiation.
CONCLUSION: In summary, the present study indicated that upregulated Fas expression following cotreatment with Poly(I:C)-HMW and IR was responsive to FasL-induced apoptosis, and combination of RLR agonist, IR, and FasL could be a potential promising cancer therapy. PMID: 31951181 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 15, 2020 Category: Cancer & Oncology Authors: Sato Y, Yoshino H, Tsuruga E, Kashiwakura I Tags: Curr Cancer Drug Targets Source Type: research

The potential targets and mechanisms of a carbazole and pyrazole containing anticancer compound.
CONCLUSION: VUGX01 can effectively block proliferation and induce apoptosis of certain type of cancer cells, even it's predicted by high LASSO score, but it is not an effective RTKs inhibitor, it may inhibit cell growth through acting as a novel ligand to one or several GPCRs. PMID: 31951182 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 15, 2020 Category: Cancer & Oncology Authors: Xie J, Gore JC Tags: Curr Cancer Drug Targets Source Type: research

Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation.
Abstract Targeting highly proliferating cells is an important issue for many type aggressive tumors. Proliferating Cell Nuclear Antigen (PCNA) is an essential protein that participates in a variety of processes of DNA metabolism, including DNA replication and repair, chromatin organization and transcription, sister chromatid cohesion. In addition, PCNA is involved in cell survival, and possibly in pathways of energy metabolism, such as glycolysis. Thus, the possibility of targeting this protein for chemotherapy against highly proliferating malignancies is under active investigation. Currently, approaches to treat ...
Source: Current Cancer Drug Targets - January 15, 2020 Category: Cancer & Oncology Authors: Cardano M, Tribioli C, Prosperi E Tags: Curr Cancer Drug Targets Source Type: research

Use of small-molecule inhibitory compound of PERK-dependent signaling pathway as a promising target-based therapy for colorectal cancer.
In conclusion, PERK inhibitor 42215 may provide an innovative treatment strategy against colorectal cancer (CRC) via the activation of the pro-apoptotic branch of the PERK-mediated UPR signaling pathway. PMID: 31906838 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2020 Category: Cancer & Oncology Authors: Rozpędek W, Pytel D, Wawrzynkiewicz A, Siwecka N, Dziki A, Dziki Ł, Diehl JA, Majsterek I Tags: Curr Cancer Drug Targets Source Type: research

Idronoxil as an Anticancer Agent: Activity and Mechanisms.
Abstract Idronoxil has been the subject of more than 50 peer reviewed publications over the last two decades. This isoflavone is an intriguing regulator of multiple signal transduction pathways, capable of causing a range of biological effects, including cell cycle arrest, apoptosis, an ability to stimulate the immune system, and inhibition of angiogenesis. These multifaceted actions suggest that idronoxil has the potential to synergize with, or complement, a wide range of cancer therapies. Whilst clinically tested in the past, idronoxil's journey was discontinued as a result of its low bioavailability in humans w...
Source: Current Cancer Drug Targets - January 2, 2020 Category: Cancer & Oncology Authors: Porter K, Fairlie WD, Laczka O, Delebecque F, Wilkinson J Tags: Curr Cancer Drug Targets Source Type: research

Hypermethylation of single CpG dinucleotides at the promoter of CXCL13 gene promote cell migration in cervical cancer.
CONCLUSION: DNA methylation-dependent CXCL13 downregulation may promote cervical carcinogenesis and progression. PMID: 31899677 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 2, 2020 Category: Cancer & Oncology Authors: Ma D, Fan SB, Hua N, Li GH, Chang Q, Liu X Tags: Curr Cancer Drug Targets Source Type: research

Disintegrin tablysin-15 suppresses cancer hallmarks in melanoma cells by blocking FAK/Akt/ERK and NF- κB signaling.
CONCLUSIONS: Tablysin-15 has reliable anti-cancer effects against M21 melanoma cells, suggesting tablysin-15 is a promising anti-tumor drug. PMID: 31893992 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 31, 2019 Category: Cancer & Oncology Authors: Deng Z, Zeng Q, Chai J, Zhang B, Zheng W, Xu X, Wu J Tags: Curr Cancer Drug Targets Source Type: research

Cancer Cell-Derived Secretory Factors in Breast Cancer Associated Lung Metastasis; their Mechanism and its Future Prospects.
Abstract In Breast cancer, Lung is the second most common site of metastasis after bone. Various factors are responsible for the mechanism of Lung metastasis occurring secondary to Breast cancer. Cancer cell-derived secretory factors are commonly known as 'Cancer Secretomes'. They exhibit prompt role in the mechanism of Breast cancer lung metastasis. They are also the major constituents of host-associated tumor microenvironment. Through cross-talk between cancer cells and the extracellular matrix components, cancer cell-derived extracellular matrix components (CCECs) such as hyaluronan, collagens, laminin and fibr...
Source: Current Cancer Drug Targets - December 20, 2019 Category: Cancer & Oncology Authors: Urooj T, Wasim B, Mushtaq S, Shah SNN, Shah M Tags: Curr Cancer Drug Targets Source Type: research

PPAR γ Agonists in Combination Cancer Therapies.
PPARγ Agonists in Combination Cancer Therapies. Curr Cancer Drug Targets. 2019 Dec 08;: Authors: Mrowka P, Glodkowska-Mrowka E Abstract Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear receptor acting as a transcription factor involved in the regulation of energy metabolism, cell cycle, cell differentiation, and apoptosis. These unique properties constitute a strong therapeutic potential that place PPARγ agonists as one of the most interesting and widely studied anticancer molecules. Although PPARγ agonists exert significant, antiproliferative and tumoricid...
Source: Current Cancer Drug Targets - December 8, 2019 Category: Cancer & Oncology Authors: Mrowka P, Glodkowska-Mrowka E Tags: Curr Cancer Drug Targets Source Type: research

Old and New Approaches to Target the Hsp90 Chaperone.
Abstract The 90-kDa heat shock protein (Hsp90) is a molecular chaperone which ensures cellular proteostasis by maintaining the folding, stabilization, activation, and degradation of over 400 client proteins. Hsp90 is not only critical for routine protein maintenance in healthy cells, but also during states of cellular stress, such as cancer and neurodegenerative diseases. Due to its ability to effect phosphorylation of numerous client proteins, inhibition of Hsp90 has been an attractive anticancer approach since the early 1990's, when researchers identified a druggable target on the amino terminus of Hsp90 for a v...
Source: Current Cancer Drug Targets - December 1, 2019 Category: Cancer & Oncology Authors: Sanchez J, Carter TR, Cohen MS, Blagg BS Tags: Curr Cancer Drug Targets Source Type: research

CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/ β-catenin Signaling.
CONCLUSION: CDK12 overexpression promotes breast cancer tumorigenesis and maintains the stemness of breast cancer by activating c-myc/β-catenin signaling. Inhibiting CDK12 expression may become a potential therapy for breast cancer. PMID: 31744448 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 17, 2019 Category: Cancer & Oncology Authors: Peng F, Yang C, Kong Y, Huang X, Chen Y, Zhou Y, Xie X, Liu P Tags: Curr Cancer Drug Targets Source Type: research

Effects of Intermittent Hypoxia on Expression of Glucose Metabolism Genes in MCF7 Breast Cancer Cell line.
This study aimed to investigate the influence of intermittent hypoxic condition on the expression of glucose metabolism genes in breast cancer MCF7 cell line. METHODS: The gene expression was analyzed using polymerase chain reaction- array method. In addition, the cell resistance, survival and migration rates were examined; to assure the hypoxic influence on the cells. RESULTS: We found that 30 hypoxic episodes induced Warburg effect through significant (p value
Source: Current Cancer Drug Targets - November 15, 2019 Category: Cancer & Oncology Authors: Jarrar Y, Zihlif M, Bawab A, Sharab A Tags: Curr Cancer Drug Targets Source Type: research

Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic.
Abstract Vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) signaling pathway is one of the most important pathways responsible for tumor angiogenesis. Currently, two monoclonal antibodies, anti-VEGF-A antibody Bevacizumab and anti-VEGFR2 antibody Ramucizumab, have been approved for the therapy of solid tumors. At the same time, VEGF/VEGFR2 signaling is involved in the regulation of immune responses. It is reported that the inhibition of this pathway has the capability to promote the vascular normalization, increase the intra-tumor infiltration of lymphocytes, and decrease the number and function o...
Source: Current Cancer Drug Targets - November 13, 2019 Category: Cancer & Oncology Authors: Gao F, Yang C Tags: Curr Cancer Drug Targets Source Type: research